Defense Health Agency Controls Over High-Risk Pharmaceutical Payments

Submitting OIG:

Department of Defense OIG

Date Issued:

Thursday, November 16, 2017

Agency Reviewed / Investigated:

Department of Defense

Submitting OIG-Specific Report Number:

DODIG-2018-033

Component, if applicable:

Defense Health Agency (DHA)

Location(s):

Agency-Wide

Type of Report:

Audit

Number of Recommendations:

View Document:

Attachment	Size
DODIG-2018-033.pdf	3.19 MB

Related Open Recommendations

No Recommendations found for this Report.

Department of Defense OIG

Department of Defense

The Department of Defense Office of Inspector General was established in 1982. The mission of the DoD OIG, as established by the Inspector General Act of 1978, as amended, (5 U.S.C. Appendix); and implemented by DoD Directive 5106.01, "Inspector General of the Department of Defense," is to serve as an independent and objective office in DoD to:

a) conduct, supervise, monitor, and initiate audits, evaluations, and investigations relating to programs and operations of the Department of Defense,

b) provide leadership and coordination and recommend policies for activities designed to promote economy, efficiency, and effectiveness in the administration of, and to prevent and detect fraud and abuse in, such programs and operations,

c) provide a means for keeping the Secretary of Defense and the Congress fully and currently informed about problems and deficiencies relating to the administration of such programs and operations and the necessity for and progress of corrective action

http://www.dodig.mil

Search form

Defense Health Agency Controls Over High-Risk Pharmaceutical Payments

Related Open Recommendations